AbbVie Inc. $ABBV Shares Bought by ABN AMRO Bank N.V.

ABN AMRO Bank N.V. increased its stake in AbbVie Inc. (NYSE:ABBV) by 1.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 933,075 shares of the company’s stock after buying an additional 9,087 shares during the quarter. AbbVie comprises 2.1% of ABN AMRO Bank N.V.’s portfolio, making the stock its 17th largest position. ABN AMRO Bank N.V. owned about 0.05% of AbbVie worth $215,206,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie in the second quarter valued at $26,000. Spurstone Advisory Services LLC acquired a new position in AbbVie in the 2nd quarter worth $28,000. Financial Gravity Companies Inc. purchased a new position in AbbVie in the 2nd quarter valued at about $36,000. Delos Wealth Advisors LLC purchased a new position in AbbVie in the 2nd quarter valued at about $39,000. Finally, Bear Mountain Capital Inc. grew its stake in shares of AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after acquiring an additional 173 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on ABBV shares. Citigroup cut their price target on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. Evercore ISI reaffirmed an “outperform” rating and issued a $228.00 target price on shares of AbbVie in a research report on Wednesday. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research report on Monday, November 3rd. Finally, Piper Sandler restated an “overweight” rating and issued a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $251.50.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised FY outlook — AbbVie reported Q4 adjusted EPS of $2.71 and revenue of $16.62B, topping estimates; management gave 2026 adjusted EPS guidance of $14.37–$14.57, above consensus, supporting the view of durable profit growth. Article Title
• Positive Sentiment: Immunology momentum — Strong demand for Skyrizi (+32% Y/Y) and Rinvoq (+29% Y/Y) drove the beat and are cited by management as the engine of revenue growth, partially offsetting Humira declines. Analysts point to continued upside from these franchises. Article Title
• Positive Sentiment: Rinvoq label expansion in progress — AbbVie submitted regulatory applications for Rinvoq (upadacitinib) in vitiligo (FDA/EMA), a meaningful new indication if approved that could support longer‑term growth. Article Title
• Neutral Sentiment: Analyst positioning mixed — Some firms (e.g., Evercore) kept bullish ratings citing immunology strength and neurology upside, while others are pausing to re‑assess targets; this is keeping trading volatile. Article Title
• Negative Sentiment: Q1 guidance missed expectations — AbbVie issued Q1 2026 EPS guidance of $2.97–$3.01 versus a ~ $3.11 consensus, and revenue guidance came in below forecasts, prompting concern about near‑term growth momentum. (Company guidance update)
• Negative Sentiment: Segment weakness and diversification worries — Aesthetics (Botox/Cosmetics) and parts of oncology showed declines and some reports flag that growth is concentrated in immunology; commentators warn the company may lean on M&A/IPR&D to sustain growth. Article Title
• Negative Sentiment: Investor skepticism on Rinvoq contribution and valuation questions — Some coverage highlights that Rinvoq’s role vs. expectations (and valuation implications for the company) remains under scrutiny despite the drug’s growth. Article Title

AbbVie Trading Down 3.8%

Shares of ABBV opened at $217.04 on Thursday. The stock has a 50 day moving average of $223.99 and a 200-day moving average of $219.14. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The firm has a market cap of $383.59 billion, a price-to-earnings ratio of 164.42, a PEG ratio of 0.93 and a beta of 0.35.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.